The role of osteoprotegerin in breast and prostate cancer

The role of osteoprotegerin in breast and prostate cancer

Detalles Bibliográficos
Main Authors:	Holen, I, Wells, J, Croucher, P, Evans, C, Lippitt, J, Coleman, R, Jagdev, S, Hamdy, F, Eaton, C
Formato:	Journal article
Publicado:	2002

Títulos similares

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
por: Eaton, C, et al.
Publicado: (2004)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
por: Holen, I, et al.
Publicado: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
por: Holen, I, et al.
Publicado: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
por: Eaton, C, et al.
Publicado: (2004)

OPG is a survival factor for breast- and prostate cancer cells in vitro
por: Holen, I, et al.
Publicado: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
por: Shipman, C, et al.
Publicado: (2000)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
por: Waterman, E, et al.
Publicado: (2007)

Role of osteoprotegerin (OPG) in cancer.
por: Holen, I, et al.
Publicado: (2006)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
por: Shipman, C, et al.
Publicado: (2002)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
por: Nyambo, R, et al.
Publicado: (2004)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
por: Croucher, P, et al.
Publicado: (2001)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
por: Croucher, P, et al.
Publicado: (2001)

Osteoprotegerin and the development of myeloma bone disease
por: Croucher, P, et al.
Publicado: (2004)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
por: Holen Ingunn, et al.
Publicado: (2009-07-01)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
por: Nyambo, R, et al.
Publicado: (2004)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
por: Shipman, C, et al.
Publicado: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
por: Croucher, P, et al.
Publicado: (2003)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
por: Croucher, P, et al.
Publicado: (2000)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
por: Jagdev, S, et al.
Publicado: (2001)

Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study.
por: Glen, A, et al.
Publicado: (2010)

Bone marrow stromal cell-derived insulin-like growth factor (IGF) II enhances growth and survival of prostate cancer cells and potentiates androgen action
por: Cross, N, et al.
Publicado: (2007)

Human bone marrow stromal cell derived IGF signaling enhances PSA production as well as proliferation/survival of androgen sensitive prostate cancer cells in vitro
por: Papageorgiou, M, et al.
Publicado: (2005)

OSTEOPROTEGERIN AS A PREDICTIVE MARKER OF THE COURSE OF BREAST CANCER
por: S. I. Zabroda, et al.
Publicado: (2015-04-01)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells
por: Cross, N, et al.
Publicado: (2008)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.
por: Cross, N, et al.
Publicado: (2008)

Imaging the effects of castration on bone turnover and hormone-independent prostate cancer colonization of bone.
por: Cross, N, et al.
Publicado: (2008)

Prostate cancer proteomics: The urgent need for clinically validated biomarkers
por: Evans, C, et al.
Publicado: (2009)

Analysis of the functional role of ADAMTS enzymes in prostate cancer
por: Molokwu, C, et al.
Publicado: (2005)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
por: De Leenheer, E, et al.
Publicado: (2004)

A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer
por: Horikawa Yohei, et al.
Publicado: (2008-08-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
por: Shipman, C, et al.
Publicado: (2002)

Osteoprotegerin in Cardiometabolic Disorders
por: C. Pérez de Ciriza, et al.
Publicado: (2015-01-01)

The roles of osteoprotegerin in cancer, far beyond a bone player
por: Yufei Wang, et al.
Publicado: (2022-05-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
por: Shipman, C, et al.
Publicado: (2003)

Loss of intercellular expression of beta-dystroglycan is a common event in prostate cancer and is significantly associated with loss of differentiation
por: Cross, S, et al.
Publicado: (2005)

Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
por: Itonaga, I, et al.
Publicado: (2000)

Expression pattern of the ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) proteinases in human prostate cancer celllines
por: Chandrasekharan, S, et al.
Publicado: (2003)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
por: Vanderkerken, K, et al.
Publicado: (2003)

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin
por: Peggy Benad-Mehner, et al.
Publicado: (2014-03-01)

Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation
por: Sarah Sohyun Park, et al.
Publicado: (2022-04-01)